Seeking 'Final Plan of Exit' for Array Business, Nanogen Starts Cutting Staff | GenomeWeb
NEW YORK (GenomeWeb News) - On the heels of Monday’s news that Nanogen is looking to sell, shut down, or find a partner for its microarray business, the company said today in a filing with the US Securities and Exchange Commission that it plans to trim its microarray workforce by 13 staffers, or around four percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.